| Literature DB >> 31906936 |
Yusuke Koizumi1,2, Takafumi Okuno3, Hitoshi Minamiguchi3, Keiko Hodohara3, Hiroshige Mikamo4, Akira Andoh3.
Abstract
BACKGROUND: Bacillus cereus sometimes causes central nervous system infection, especially in compromised hosts. In cases of meningitis arising during neutropenia, CSF abnormalities tend to be subtle and can be easily overlooked, and mortality rate is high. We report a survived case of B. cereus meningitis/brain abscess in severe neutropenia, presenting as immune reconstitution syndrome. CASEEntities:
Keywords: Bacillus cereus; Bacteremia; Febrile neutropenia; Immune reconstitution syndrome; Meningitis
Mesh:
Substances:
Year: 2020 PMID: 31906936 PMCID: PMC6945728 DOI: 10.1186/s12879-019-4753-1
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Three Types of Central Nervous System Bacillus cereus Infection
| Post-Surgical Procedure/Device Infection | Neonatal Infection | Severe Neutropenia | |
|---|---|---|---|
| Risk Population | Ommaya reservoir | Premature birth: 32 (27–36) weeks | WBC count <100/uL |
| Post intrathecal injection | Low body weight infant:1500 (830–3760) g | Induction therapy against AML | |
| Disease Onset | Several days after procedures | 7 (1–49) days after birth | Around 10 days of neutropenia |
| Mode of Infection | Meningitis | Meningoencephalitis | Necrotizing meningoencephalitis |
| Ventriculitis | Cerebral hemorrhage | ||
| Brain abscess | Subarachnoid hemorrhage | ||
| Clinical Course and Prognosis | Responds well to antimicrobial therapy | Progresses within hours | Progresses within hours |
| Leads to death within days | Leads to death within days | ||
| Cerebrospinal Fluid Findings | Up to 105 cells /mm3 | Around 102–3 cells /mm3 | Around 102 cells /mm3 |
| Mortality rate | Low | 75% (12/14 cases) | 79% (11/14 cases) |
| References | 3 | 3, 4 | 3, 6–14 |
Clinical Characteristics of Neutropenia-Related Bacillus cereus Meningitis
| Symptoms at Onset | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Year | Age | Underlying Diseases | WBC Count at Onset | Fever | Headache | Vomiting | Diarrhea | Abdominal Pain | Neurological Abnormalities | CNS Disease | Treatment | Outcome | Reference |
| 1 | 1973 | 63 | AML | 400a | + | Coma | Brain abscess | GM, OXA, CBC | Dead | 5 | ||||
| 2 | 1981 | 19 | AML | <100 | + | Meningitis | GM, PCG | Dead | 6 | |||||
| 3 | 1988 | 67 | MDS/AML | 100a | + | + | + | Meningoencephalitis/SAH | GM, LM, PIPC | Dead | 7 | |||
| 4 | 1989 | 3 | ALL | 20 | + | Lethargy | Brain abscess | CP, VCM, GM, RFP | Alive | 8 | ||||
| 5 | 1995 | 26 | AML | 20 | + | Visual disturbance | Meningoencephalitis/SAH | CAZ | Dead | 9 | ||||
| 6 | 1997 | 64 | AML | 300 | + | + | + | Meningoencephalitis/SAH | PIPC, GM, CPZ, CTX, ABPC | Dead | 10 | |||
| 7 | 1997 | 20 | ALL | 0 | + | + | + | + | Speech disturbance, Sensory disturbance | Cerebral infarction (basal ganglia) | Dead | 11 | ||
| 8 | 1999 | 13 | ALL | 0 | + | + | Meningoencephalitis/hydrocephalus | Alive, Severe sequelae | 11 | |||||
| 9 | 1999 | 15 | ALL | 0 | + | + | Meningoencephalitis | Dead | 11 | |||||
| 10 | 1999 | 30 | AML | <100 | + | + | Delirium, hyperventilation | Necrotic meningoencephalitis | CAZ, AMK | Dead | 12 | |||
| 11 | 1999 | 43 | AML | <100 | + | + | + | + | + | Delirium, decerebrate rigidity | Meningoencephalitis | CAZ, AMK → VCM, GM & others | Dead | 12 |
| 12 | 1999 | 14 | ALL | <100 | + | Delirium, epilepsy, coma | Meningoencephalitis | CAZ, AMK & others | Dead | 12 | ||||
| 13 | 2003 | 16 | AA | 90 | + | + | Nuchal rigidity, epilepsy, consciousness disturbance | Meningoencephalitis | CAZ, IPM/CS | Dead | 13 | |||
| 14 | 2005 | 19 | HD | 0 | + | Confusion, epilepsy, hemiparesis | Meningoencephalitis | ABPC, AMK, CPFX, TEIC, CLDM | Alive | 14 | ||||
| Our | case | 54 | AML | <100 | + | + | + | disorientation, slurred speech, and confusion | Meningoencephalitis/hydrocephalus brain abscess | MEPM, LZD, VCM | Alive | |||
adenotes the number of neutrophils
Abbreviations: AA Aplastic anemia, ABPC Ampicillin, ALL Acute lymphoblastic leukemia, AMK Amikacin, AML Acute myelogenous leukemia, CAZ ceftazidime, CBC, carbenicillin, CLDM Clindamycin, CNS Central nervous system, CP Chloramphenicol, CPFX Ciprofloxacin, CPZ Cefoperazone, CTX Cefotaxime, GM Gentamicin, HD Hodgkin disease, IPM/CS Imipenem/cilastatin, LM Lincomycin, LZD Linezolid, MDS Myelodysplastic syndrome, MEPM Meropenem, OXA Oxacillin, PCG Penicillin G, PIPC Piperacillin, RFP Rifampin, VCM Vancomycin
Fig. 1Clinical course. The figure indicates the clinical course of the patient from day 5 to day 48, when clinical symptoms resolved. The line plot shows the trend in blood leukocytes (above) and CSF cells (below). The vertical rectangle indicates the percentage of polymorphonuclear cells (red) in the CSF. On day 5, CSF showed moderate pleocytosis, with conspicuous protein increase. Antibiotic therapy was effective, leading to defervescence and neurological improvement. On day 13, however, fever and nuchal rigidity worsened. CSF findings showed 130 cells/μL with an increased proportion of polymorphonuclear cells. The MRI findings on day 15 revealed abscess lesions (arrow heads) and meningeal thickening (arrows). On day 19, meningism worsened remarkably, and CSF cells peaked at 2040 cells/μL with 98% polymorphonuclear cells. Other causes were ruled out, and meropenem, vancomycin, and linezolid were continued. Gradually, MRI and CSF findings improved and the patient was discharged without sequelae. Note that the inflammatory findings, such as CSF cells, sIL-2R, and ADA were dramatically enhanced in response to the recovery of blood leukocyte count. The reference ranges are; Blood leukocytes 3000-8000/μL, CSF cells 0–5/μL, CSF protein 10–40 mg/dL, CSF glucose 50–80 mg/dL, and CSF sIL-2R, <50 U/mL